SKP.L Share News (SKP)

BUZZ-View from the buyside: SLI's Nimmo backing UK small-cap pharma stocks

** Standard Life Investments' Harry Nimmo cites small-cap pharma stocks as one of his highest conviction ideas in his SLI UK Smaller Companies investment trust ** Manager bought into Skyepharma in the six months ending 31 December, according to his trust's half-yearly report released on Mon

SkyePharma To Repay Remainder Of CRC Finance Facility Early

Sector movers: GSK leads defensive pharma stocks higher

A massive cash return by Glaxosmithkline gave the wider sector a lift on Wednesday, with defensive healthcare and pharmaceutical stocks also benefiting from a reduction in risk appetite as UK markets pulled back from a five-month high. Sales, profits and earnings slumped during the fourth quarter of

BUZZ-SkyePharma: disappointing sales hit shares

** SkyePharma dives to lowest levels in more than 4 mths on lower-than-expected GlaxoSmithKline Q3 2014 sales of Relvar/Breo Ellipta and Anoro Ellipta, which both use SkyePharma licensed technology [ID: ** Stock, which has had great run over the past year, rising around 200 pct, down 16.5 p

Skyepharma To Meet Expectations But Glaxo Royalties Slower

Skyepharma climbs after launching Flutiform in Spain and Italy

Skyepharma shares moved higher on Monday after the drug-maker announced that its Flutiform product has been launched in Spain and Italy. The group also announced its 120-puff version of Flutiform has been launched in Japan by its licensing partner, Kyorin Pharmaceuticals. The drug, which is used fo

SkyePharma Says Sales Momentum Has Continued Since August

Tuesday broker round-up UPDATE

AVEVA: JP Morgan reduces target price from 2450p to 1825p, while leaving its overweight rating unchanged. African Minerals: Credit Suisse reduces target price from 120p to 25p, while leaving its neutral rating unchanged. Aviva: Goldman Sachs ups target price from 490p to 515p and reiterates a neutr

SkyePharma To Pay Back Euro Element Of Loan To Reduce Finance Costs

UK MORNING BRIEFING: Scotland-Exposed Stocks Lead Opening Declines

Skyepharma Partner Announces Phase III Flutiform Study Results

Skyepharma profits rise on Flutiform growth but rivals hit royalties

Drug developer Skyepharma reported continued growth of its asthma inhaler Flutiform, but said royalties on some products were falling due to more competition. Skyepharma doubled sales of Flutiform compared with the second half of 2013 and launched the product in eight more countries including Franc

Skyepharma Trading As Expected As Loss Widens On Bond Settlement

UK MORNING BRIEFING: Flat Start As Investors Mull Central Bank Votes

*Skyepharma Says Prospects Remain In Line With Its Expectations